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Monoclonal antibodies (mAbs) directed against the 
transferrin receptor are known to inhibit proliferation 
of cells due to iron deprivation. Some cell types, how- 
ever, escape from growth inhibition by a mechanism 
which is unclear at present. This mechanism is the sub- 
ject of the present study. We investigated the differen- 
tial growth inhibition caused by anti-transferrin recep- 
tor mAb ER-MP21 in connection with the differentia- 
tion of murine macrophages (M+). Therefore, we 
applied two models of M4 differentiation, namely, cul- 
ture of bone marrow cells in the presence of M-CSF and 
a panel of M+ cell lines ordered in a linear differentia- 
tion sequence. In both models we observed that prolif- 
eration of M4 precursors was strongly inhibited by ER- 
MP21. In contrast, proliferation of more mature stages 
of M~#I differentiation was hardly affected. Remarkably, 
iron uptake by M4 precursor and mature M+ cell lines 
was inhibited by ER-MP21 to the same extent. Row- 
ever, mature M4 cell lines showed an iron uptake two- 
to threefold higher than that of M+ precursor cell lines. 
These observations strongly suggest that mature M+ es- 
cape from ER-MPBl-mediated growth inhibition, be- 
cause these cells take up more iron than is actually 
needed for proliferation. Furthermore, we found that 
enhanced iron uptake by mature MI#J is not necessarily 
accompanied by a higher cell surface expression of 
transferrin receptors, thus suggesting an increased re- 
cycling of transferrin receptors in mature M4. o lsso 
Academic Press, Inc. 
INTRODUCTION 
In previous studies we reported on the phenotypical 
differentiation of murine M4,’ using mAbs directed 
against cell surface molecules [l, 21. In search of func- 
’ To whom reprint requests should be addressed. 
’ Abbreviations used: BSA, bovine serum albumin; M-CSF, macro- 
phage-colony stimulating factor; Mg, macrophage(s); mAb, mono- 
clonal antibody; SDS, sodium dodecyl sulfate. 
tionally important epitopes, involved in the regulation 
of M$I differentiation, we produced new mAbs against 
Mc$ precursor antigens [3] and screened these mAbs for 
interference with M4 colony development in M-CSF- 
stimulated bone marrow cultures. One of these mAbs, 
termed ER-MP21, appeared to inhibit the in vitro devel- 
opment of M4 by hindering M4 precursor proliferation. 
Moreover, the proliferation of MC#I precursor cell lines 
was strongly inhibited by ER-MP‘X In contrast, mature 
M@ cell line proliferation was hardly affected. Pilot stud- 
ies using 5sFe-loaded transferrin indicated that mAb 
ER-MP21 inhibited the iron uptake by M$ and is there- 
fore most likely directed against the murine transferrin 
receptor. 
Using other anti-transferrin receptor mAbs, a similar 
differential inhibitory effect on the proliferation of 
different cell lines has been observed by other investiga- 
tors as well 14, 51. Additionally, different protocols for 
induction of normal T- and B-lymphocyte proliferation 
show different degrees of sensitivity toward the inhibi- 
tory action of an anti-transferrin receptor mAb [6]. The 
mechanism of differential growth inhibition by a partic- 
ular anti-transferrin receptor mAb remains, however, 
unclear at present [7]. In general, inhibitory anti-trans- 
ferrin receptor mAbs cause iron deprivation and thus 
withhold cells from a vital element in their metabolism 
[4,5,8]. However, it remains to be established whether 
insensitive cell types are deprived from iron to a lesser 
extent upon culture with a particular anti-transferrin re- 
ceptor mAb, or, alternatively, employ additional mecha- 
nisms for iron uptake other than the transferrin re- 
ceptor. 
Our initial finding of differential inhibition of M@ pro- 
liferation by ER-MPPl prompted us to a detailed analy- 
sis of the functional properties of this anti-transferrin 
receptor mAb. In the present study we substantiate the 
differential inhibition of M@ proliferation by ER-MPZl 
and show that growth inhibition is inversely correlated 
to macrophage maturation. Furthermore, we investigate 
the mechanism of differential sensitivity for growth in- 
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TABLE 1 
Cell Lines Used 
Cell line Cell type Ref. 
R2C4 
RlBl 
RMB-TG 
WEHI- 
RAW309Cr.l 
WR19M.l 
RLD-1 
SP2/0 
M+ precursor hybrid 
M# precursor hybrid 
MI$ precursor, myelocyte 
Immature M@ 
Mature M& 
Mature M+ 
Pre-T cell 
B cell 
191 
PI 
PI 
[lo, 21 
Ill,21 
w, 21 
w, 21 
1131 
hibition by ER-MP21, using a panel of M+ cell lines ar- 
rested in different, previously defined stages of M&J 
differentiation [2, 91. The results show that ER-MP21 
equally inhibits iron uptake by M4 precursor and ma- 
ture MC#J cell lines. However, mature M~#J cell lines exhibit 
a level of iron uptake significantly higher than that of 
MC#J precursor cell lines. These data suggest that mature 
Mb escape from ER-MPBl-mediated growth inhibition 
because these cells take up iron in amounts greater than 
those needed merely for proliferation. 
MATERIALS AND METHODS 
Mice. Male and female BALB/c mice were purchased from Olac 
(Bicester, Oxon, UK). Animals were kept under clean, routine labora- 
tory conditions with free access to food and water. 
Cells and culture conditions. The cell types and differentiation 
stages of the cell lines used in the present study are summarized in 
Table 1. The Mb precursor cell lines RlBl and R2C4 were hybrids 
obtained by fusion of RMB-TG myeloid cells and M$ derived from M- 
CSF-stimulated bone marrow culture [9]. All cell lines were cultured 
in DMEM (Flow Laboratories, Irvine, Scotland), supplemented with 
10% SERUM-PLUS (KC Biological, Lenexa, KS) and antibiotics. M- 
CSF-stimulated bone marrow cultures were performed in 24-wells cul- 
ture plates (Costar, Cambridge, MA) with L-cell-conditioned medium 
as the source of M-CSF, essentially as described by Van der Meer et 
al. [14]. 
Quunti&ation of cell proliferation. Cell lines were set into culture 
in 96-wells culture plates in low density, ensuring exponential growth 
after 3 days. Then, after 3 days of culture in the presence or absence 
of mAbs, resulting cell numbers were quantified using the calorimetric 
MTT assay as described by Mosmann [Xi]. For M-CSF-stimulated 
bone marrow cultures, resulting progeny was quantified similarly after 
7 days. 
Antisera and conjugates. The IgG2a anti-transferrin receptor mAb 
ER-MP21, as well as the control IgG2a mAbs ER-MPPO, ER-MP39, 
and ER-MP42, were produced by hybridomas, obtained after fusion of 
Y3 myeloma cells with spleen cells from a Lewis rat that had been 
immunized with M$ precursor hybrid cells [3]. Hybridoma cells, se- 
creting the anti-transferrin receptor mAb H129.121 (Ref. [IS]) were 
kindly provided by Dr. Michel Pierres (INSERM-CNRS, Marseille, 
France). For application in culture, mAbs were purified from ascitic 
fluid (l/l diluted in PBS) by 18% Na$O, precipitation (w/v; final 
concentration), desalted using Sephadex G-25M columns (Pharmacia, 
Uppsala, Sweden), and filter-sterilized. In flow-cytometric experi- 
ments, we used FITC-coupled F(ab)z fragments of rabbit anti-(rat- 
IgG) (Cappel, Malvern, PA) to detect rat mAb binding to cells. 
mAb and transferrin purification and radiolabeling, ER-MP21 
mAb purification for binding affinity studies was achieved by specific 
adsorption and subsequent elution from a column of mouse anti-rat 
kappa (MARK-l) coupled Sepharose-4B beads [17]. Murine transfer- 
rin was purified from pooled normal mouse serum by affinity chroma- 
tography over rabbit anti-rat transferrin coupled to Sepharose-4B 
(Ref. [18]), taking advantage of immunological cross-reactivity be- 
tween rat and mouse transferrin. Iron removal from purified transfer- 
rin and reloading with 6BFe was performed as described before, using 
the nitrilotriacetic acid method [lS]. Radio-iodination of ER-MPPI 
mAb and transferrin was performed with 125I Na (Amersham Radio- 
chemical Centre, UK) using lodogen reagent (Pierce Chemical, Rock- 
ford, IL) as catalyst [20]. 
“Fe uptake studies. Cellular iron uptake from 59Fe-loaded trans- 
ferrin was determined essentially as described by Verhoef and Noorde- 
loos [21]. Briefly, cells were harvested, washed at least twice with se- 
rum-free DMEM, and resuspended in DMEM supplemented with 
0.5% (w/v) bovine serum albumin. Cells (1-4.106/ml) were incubated 
in siliconized vials for 30 min at 37°C in the presence or absence of 
mAh (20 fig/ml). Then, 5sFe-loaded transferrin (5 pg/106 cells) was 
added. At various times, duplicate samples of 0.5 ml were taken and 
iron uptake was stopped immediately by adding 5 ml ice-cold PBS. 
Cells were washed three times in ice-cold PBS and cell-bound radioac- 
tivity was measured in a Packard Autogamma 500-C spectrometer. 
In all experiments, nonspecific cell-bound radioactivity-usually less 
than 1 pmol/lOs cells-was subtracted from the obtained experimen- 
tal values. 
Radiolabeled mAb and Tf binding stuciies. For determination of 
binding of rz51-labeled ER-MP21 or ‘261-labeled transferrin, all steps 
were performed on ice. Cells were washed with DMEM and resus- 
pended at a concentration of 5.106 cells/200 ~1 in DMEM containing 
0.5% BSA as described above. In competitive binding studies, preincu- 
bation was performed with 100 ~1 potentially blocking nonradioactive 
reagents for 30 min. Next, 100 ~1 rz61-labeled ER-MP21 or ?-labeled 
transferrin, diluted in DMEM + 0.5% BSA to the concentration indi- 
cated, was added to the cells. In binding affinity determination, dilu- 
tion series were used with and without loo-fold excess of unlabeled 
ligand to assess nonspecific binding. Cells were incubated under regu- 
lar mixing for 3 h to equilibrate ligand binding. Then, cell-bound and 
free radioactivities from 100 ~1 aliquots were separated by spinning 
the cells through 300 ~1 of an oil mixture of dinonylphtalate and dibu- 
tylphtalate (3:7.5) in 0.4-ml reaction vessels (Eppendorf, Hamburg, 
FRG), as adapted from Klausner et al. [22]. The tubes were frozen in 
liquid nitrogen and cut with a heated surgical blade. Cell-bound and 
free radioactivity were measured as indicated. For affinity determina- 
tion, binding data were analyzed according to Scatchard [23]. 
Antigen characterization. The molecular mass of the antigens rec- 
ognized by ER-MP21 and H129.121 mAb was determined by surface 
..’ iodination of cells, followed by specific immunoprecipitation and 
SDS-PAGE analysis, essentially as described by Pont et al. [24]. 
Zmmun&wrescence labeling and flow-cytometric analysis. Cells 
were labeled for immunofluorescence as described previously [2]. 
Analysis was performed on a FACScan (Becton-Dickinson, Sunny- 
vale, CA) with logarithmic amplification. Antibody binding was quan- 
tified by interpolation on a calibration scale, using quantitative flue- 
rescent micro bead standards (Becton-Dickinson). Thus, antibody 
binding is expressed as soluble FITC molecular equivalents (moleq. 
FITC). 
RESULTS 
I. ER-MP21 Recognizes the Murine Transferrin 
Receptor but Does Not Compete with 
Transferrin Binding 
In order to discover epitopes that are of functional im- 
portance in the course of Md differentiation, we 
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FIG. 1. Inhibition of macrophage development in M-CSF stimu- 
lated bone marrow culture by ER-MP21. Murine bone marrow was 
cultured with M-CSF in the presence or absence of different concen- 
trations of mAb. After 7 days the mature Mb progeny obtained was 
quantified using the calorimetric MTT assay. 
screened several anti-M4 precursor mAbs for interfer- 
ence with M+ differentiation in M-CSF stimulated bone 
marrow cultures. The rat IgG2a mAb, termed ER-MP21, 
appeared to inhibit the development of mature bone 
marrow-derived M+ in a dose-dependent manner (Fig. 
1). Maximal inhibition was reached at ER-MP21 con- 
centrations higher than 5 pg/ml. In contrast, control rat 
IgG2a mAbs (ER-MP39 shown as example), which rec- 
ognize other molecules on M4 precursor cells, caused no 
inhibition of M4 development, even at the highest con- 
centration tested (30 pg/ml). 
Inhibition of iron uptake by anti-transferrin receptor 
mAbs is a well-known cause of inhibition of proliferation 
[7]. Therefore, we examined the effect of ER-MP21 on 
cellular iron uptake. Figure 2 shows that ER-MP21 in- 
deed inhibits iron uptake from 5gFe-loaded transferrin in 
a dose-dependent manner. The question arises whether 
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ER-MP21 and Transferrin Have Different Binding Sites on 
Transferrin Receptors 
Ligand bound 
(pmole/3 X lo6 cells) 
Preincubation ?-labeled ligand Expt. I Expt. II 
- Mu-Tf” 0.62 0.52 
Rat-Tf* Mu-Tf 0.48 nd 
NMS’ Mu-Tf nd 0.30 
ER-MP21* Mu-Tf 0.63 0.45 
ER-MP20* Mu-Tf 0.60 0.43 
- ER-MP21d 0.45 0.44 
Rat-Tf’ ER-MP21 0.41 nd 
NMS’ ER-MP21 nd 0.45 
ER-MP21’ ER-MPPl 0.07 0.08 
ER-MPPO’ ER-MPPl 0.42 0.40 
Note. RAW309Cr.l cells were assayed for competitive binding of 
murine transferrin (Mu-Tf), anti-transferrin receptor mAb ER- 
MP21, rat transferrin (rat-Tf), or normal mouse serum (NMS) on ice, 
using the concentrations indicated. Rat mAb ER-MP20 served as ir- 
relevant IgG2a control. 
’ Ligand [‘261-Mu-Tf] = 1 X 10m6 M. 
‘Preincubation [rat-Tf] = [ER-MPSl] = [ER-MPPO] = 1.3 
x 1o-6M. 
’ Preincubation NMS = 33%. 
d Ligand [1261-ER-MP21] = 1 X 10m7 M. 
‘Preincubation [rat-Tf] = [ER-MPPl] = [ER-MPZO] = 1.3 
x 1O-6 M. 
inhibition of iron uptake is mediated through competi- 
tion between transferrin and ER-MP21 for the same 
binding site at the transferrin receptor. To investigate 
this possibility, RAW309Cr.l cells were incubated with 
1251-labeled transferrin or ‘251-labeled ER-MP21, with or 
without preincubation with excess unlabeled transfer- 
rin, ER-MP21, or irrelevant IgG2a mAb ER-MPBO. The 
results, presented in Table 2, clearly show that ER- 
d I 
O-l I I I 
0 10 20 30 JO 
[ER-Ml’211 in rJe/ml 
FIG. 2. Inhibition of iron uptake by ER-MP21. (left) Specific ‘qe-uptake by the mature M$ cell line WR19M.l in the absence and the 
presence of 25 pg/ml ER-MPPl or 25 pg/ml ER-MP42 control mAb. The slight inhibition of iron uptake in the presence of ER-MP42 was not 
observed in other experiments. (right) Dose-dependency of ER-MP21-mediated inhibition of we-uptake by the mature M$ cell line 
RAW309Cr.l. Cells were incubated with mAb for 30 min at 37°C prior to the addition of 6BFe-transferrin. 
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FIG. 3. Immunoprecipitation of transferrin receptors by mAbs 
ER-MP21 and H129.121 from lSI-labeled WR19M.l cells. Precipi- 
tated transferrin receptors were run on a 10% polyacrylamide gel un- 
der reducing and nonreducing conditions. mAb H129.19, directed 
against murine CD4, was used to detect nonspecifically binding pro- 
teins. 
MP21 and transferrin have different binding sites on the 
transferrin receptor, since preincubation of cells with 
ER-MP21 caused no significant inhibition of lz51-labeled 
transferrin binding, and vice versa. Similar results were 
obtained when R2C4 M$J precursor cells were used (data 
not shown). We have no reasonable explanation for the 
relatively high nonspecific binding of lz51-labeled trans- 
ferrin in these experiments. 
To confirm the notion that ER-MP21 recognizes the 
murine transferrin receptor, we immunoprecipitated the 
ER-MP21 antigen from ‘*‘I-labeled cells and assessed its 
molecular mass by SDS-PAGE followed by autoradiog- 
raphy. Figure 3 shows that ER-MP21 precipitates an an- 
tigen of the same apparent molecular mass as the murine 
transferrin receptor, precipitated by mAb H129.121 
(Ref. [16]). Both mAbs recognize a complex of 200 kDa, 
consisting of two identical chains of 100 kDa. 
In summary, rat mAb ER-MP21 inhibits murine Md, 
development in M-CSF-stimulated bone marrow cul- 
ture. ER-MP21 recognizes the murine transferrin recep- 
tor, since the mAb inhibits cellular uptake of 5gFe-trans- 
ferrin and precipitates a glycoprotein of molecular mass 
identical to that of the murine transferrin receptor. 
However, ER-MP21 does not interfere with transferrin 
binding to the receptor. 
II. ER-MP21 Inhibits Proliferation of M4 Precursors, 
but Not of Mature Mc$ 
We then approached the question whether prolifera- 
tion of different M4 differentiation stages is equally 
affected by ER-MP21. This was investigated in two in 
vitro models of M4 differentiation, viz., M-CSF-stimu- 
lated bone marrow culture and a panel of M$ cell lines, 
which previously has been ordered in a differentiation 
sequence on the basis of functional and phenotypical 
characteristics [2]. 
In M-CSF-stimulated bone marrow cultures, M@ de- 
velop from M4 precursors by the action of the lineage- 
specific growth factor M-CSF. The relative maturity of 
the proliferating cells steadily increases with time dur- 
ing the first days of culture [14]. In order to assess the 
inhibitory effect of ER-MP21 on proliferation of cells in 
different stages of M@ differentiation, we added mAb (30 
pg/ml) to bone marrow cultures at different days and 
quantified the resulting MG progeny at Day 7 after onset 
of culture. Parallel cultures were irradiated on the same 
days with 1500 rad y-radiation as 100% growth inhibi- 
tion controls. This radiation dose prevented further pro- 
liferation of the cells, but allowed terminal differentia- 
tion. When ER-MP21 was added at Day 0, the total cell 
count at Day 7 was less than 10% of the untreated con- 
trols (Fig. 4, left). In contrast, addition of mAb at Day 
4 of culture hardly affected the magnitude of resulting 
progeny at Day 7 (93% of control). For all irradiated and 
ER-MPBl-treated cultures, the number of cell cycles 
was calculated that treated cultures were left behind 
compared to untreated controls. The retarded cell cycle 
numbers thus obtained for the irradiated cultures were 
taken as 100% growth inhibition controls. Then, the re- 
tarded cell cycle numbers obtained for ER-MPBl- 
treated cultures were expressed relative to the irradia- 
tion-treated controls, thus revealing a relative growth 
inhibition for the M~#I precursors present on the respec- 
tive days of mAb addition (Fig. 4, right). Clearly, bone 
marrow M4 precursors (assayed at Day 0) were very sen- 
sitive to growth inhibition by ER-MP21, whereas the 
more mature cells present in culture at Day 4 were 
hardly affected. 
The second model of M$J differentiation, in which the 
inhibitory effect of ER-MP21 was examined, was a panel 
of M4 cell lines aligned according to their differentiation 
stage [2], supplemented with the M4 precursor hybrids 
R2C4 and RlBl (Ref. [9]; see Table 1). Figure 5 shows 
that proliferation of M$ precursor (R2C4, RlBl, and 
RMB-TG) and immature M4 (WEHI-3) cell lines was 
strongly inhibited. Most R2C4 cells died in the presence 
of ER-MP21. In contrast, proliferation of the mature 
M4 cell lines RAW309Cr.l and WR19M.l was only mar- 
ginally influenced by ER-MP21. A similar differential 
growth inhibition was observed for non-M9 cell lines as 
well: RLD-1 pre-T cells died during 3 days of culture in 
the presence of ER-MP21, whereas proliferation of SP2/ 
0 myeloma cells was not inhibited. 
Thus, in two models of M4 differentiation we observed 
that anti-transferrin receptor mAb ER-MP21 strongly 
inhibited proliferation of M4 precursors, whereas prolif- 
DIFFERENTIAL GROWTH INHIBITION BY ANTI-TRANSFERRIN RECEPTOR mAb 
day of irradiation or MAb addition day of MAb addition 
FIG. 4. Differentiation stage-dependent inhibition of M4 proliferation by ER-MP21 in M-CSF-stimulated bone marrow cultures. (left) 
M@ progeny at Day 7 in cultures, treated in parallel on various days by irradiation (1500 rad 6oCo y-radiation, black bars) or addition of ER- 
MP21 (30 pg/ml final concentration, hatched bars). Cell numbers were quantified using the MT? assay and expressed relative to untreated 
controls. (right) Relative growth inhibition calculated from data represented in Fig. 4, left. For mAb- or radiation-treated cultures, the number 
of cell cycles needed to reach the cell number in untreated controls was calculated. Values obtained for irradiated cultures were taken as 100% 
inhibition controls and values for ER-MP21-treated cultures were expressed relative to these. 
eration of more mature stages of M$ differentiation was 
hardly affected. 
III. ER-MP21 Equally Inhibits Fe Uptake of M@ 
Precursor and Mature M4 Cell Lines, but 
the Latter Show a Higher Fe Uptake 
We then approached the question of what the mecha- 
nism of differentiation-stage correlated inhibition of M4 
proliferation by ER-MP21 was. Therefore, we investi- 
gated the iron uptake by the various cell lines in the ab- 
sence and the presence of ER-MP21 (Fig. 6, left). The 
presence of ER-MP21 (20 pg/ml) reduced the uptake of 
5gFe for all tested cell lines to an average of 35% (range 
RN309Cr.l 
WR19M.l 
0 i0 -. 40 ab i0 100 
proliferation (cell cycles; % control) 
FIG. 6. Differentiation stage-dependent inhibition of M@ pro- 
liferation by ER-MP21 in a panel of M#J cell lines. Mg precursor 
(RZC4, RlBl, RMB-TG), immature M$I (WEHI-3), mature M& 
(RAW309Cr.1, WRlSM.l),pre-T (RLD-l), andmyeloma (SP2/0) cell 
lines were cultured in the presence or the absence of ER-MPPl(20 pg/ 
ml) or control IgG2a mAb (not shown). After 3 days, cell numbers in 
parallel cultures were quantified using the MTT assay. Proliferation is 
given as number of cell cycles performed relative to untreated controls. 
28-51s) of untreated control value, irrespective of 
differentiation stage or cell type. However, mature M$ 
cell lines showed a 5gFe uptake two- to threefold higher 
than that of M4 precursor and immature M4 cell lines, 
both in the absence and in the presence of ER-MP21. 
This difference cannot be ascribed to significant differ- 
ences in cell size of the various cell lines as determined 
by flow-cytometric forward light scatter analysis (data 
not shown). Hence, for the cell lines of the M4 lineage, 
the proliferation in the presence of ER-MP21 correlates 
highly to the residual iron uptake in the presence of the 
mAb (Fig. 6, right; r = 0.86). This relationship appears 
to be strongly cell-type dependent. SP2/0 myeloma cells, 
namely, grew undisturbedly on a level of residual iron 
uptake as low as 1 pmol/106 cells/h, whereas prolifera- 
tion of R2C4 M@ precursor cells was completely inhib- 
ited at the same low level of iron uptake. 
IV. M4 Precursor and Mature M$ Cell Lines Express 
Similar Numbers of Slightly Different 
Transferrin Receptors 
The most likely explanation for increased iron uptake 
by mature M$ cell lines, compared to that of M4 precur- 
sor and immature M4 cell lines, is an increased cell sur- 
face expression of transferrin receptors. To affirm this 
supposition, we examined the transferrin receptor ex- 
pression by the M4 cell line panel semiquantitatively us- 
ing the flow cytometer. Simultaneously, 5?Fe uptake was 
determined for another part of the same cell prepara- 
tion. In different experiments, transferrin receptor ex- 
pression on M$ precursor and immature Mc$ cell lines 
varied from approximately 1 to 4 X 10’ mol.eq. FITC, 
depending on cell line and culture density (Fig. 7). In- 
deed, the mature M$ cell line WR19M.l showed an in- 
creased transferrin receptor expression (5-6 X 10’ 
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FIG. 6. (left) ER-MP21-mediated inhibition of iron uptake by M@ and non-M& cell lines. %Fe uptake was measured in M# precursor 
(R2C4, RlBl, RMB-TG), immature Mb (WEHI-3), mature Md (RAW309Cr.1, WRlSM.l), pre-T (RLD-l), and myeloma (SP2/0) cell lines in 
the absence (black bars) or presence (hatched bars) of ER-MP21. Data represent the mean of at least four determinations per cell line -+ SEM. 
(right) Correlation between residual iron uptake by the various cell lines and proliferation in the presence of ER-MPPl. Data represented in 
Figs. 5 and 6, left, are combined in this figure. 
mol.eq. FITC), which related to an increased iron up- 
take. Surprisingly, the mature RAW309Cr.l cells 
showed a transferrin receptor expression comparable to 
the expression found for M4 precursor and immature 
M4 cell lines (2 X lo6 mol.eq. FITC). Iron uptake by 
RAW309Cr.l cells, however, was three-fold higher. Ap- 
parently, RAW309Cr.l cells endocytosed as much as 
three times the amount of transferrin-bound iron than 
did M4 precursor cells, using the same number of cell 
surface transferrin receptors. 
As such, the expression of transferrin receptors by the 
investigated M+ cell lines showed no obvious correlation 
with the expression of other differentiation stage-related 
markers (cf. Refs. [2, 91). The observation that 
20 
-2 
RAW309Cr.l 
P t 
Os-..,.,..,........,,,,.,,,.,,,,.,,,,,,.,,.,,.,‘..l..~ 
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ER-MP21 binding (mol.eq. FITC x 1g3 ) 
FIG. 7. Relationship between cell surface transferrin receptor ex- 
pression and iron uptake for different M$J cell lines. Part of a cell prep- 
aration was processed for immunofluorescence and used to quantify 
ER-MP21 binding by flow cytometry. For another part of the same 
preparationS8Fe uptake was measured. Each point represents the ER- 
MP21 binding and ‘?Fe uptake determined in a single experiment. 
Data from different experiments on the same cell line are connected. 
RAW309Cr.l cells internalized far more iron than M4 
precursor cells, using the same number of transferrin re- 
ceptors, raised the question whether transferrin recep- 
tors on mature M4 cell lines, in particular on 
RAW309Cr.l cells, are structurally different from trans- 
ferrin receptors on M4 precursor and immature M$J cell 
lines. From binding affinity studies using 1251-labeled 
ER-MP21 we obtained circumstantial evidence that 
this is indeed the case. Figure 8 (left) shows that ER- 
MP21 bound to R2C4 transferrin receptors with a 
single affinity (& = 19-23 X lo-’ M). Remarkably, 
RAW309Cr.l cells showed two types of receptors with 
different affinities for ER-MP21 (Fig. 8, middle). High- 
affinity receptors on RAW309Cr.l cells bound the mAb 
more avidly (& = 7.3 X lo-‘M; range 5.7-9.0 X lo-‘M) 
compared to R2C4 transferrin receptors. These analyses 
also confirmed the preceding data (Fig. 7), namely, that 
R2C4 and RAW309Cr.l cells express similar numbers of 
transferrin receptors. In different experiments ER- 
MP21 binding sites on R2C4 cells ranged from 2-13 
X lo4 per cell (Fig. 8, left), whereas the high affinity 
binding sites on RAW309Cr.l cells ranged from 3-10 
X lo* per cell (Fig. 8, middle), depending on culture den- 
sity of the cells [ 251. 
A likely candidate for the ER-MP21 low-affinity re- 
ceptor on RAW309Cr.l cells (I& * 4.5 X 10V7M) is the 
receptor for the Fc part of IgG, which is known to be 
expressed by mature M4 cell lines [26]. Therefore, we 
performed the same binding affinity studies in the pres- 
ence of 1.3 X low6 M isotype control mAb ER-MPBO. 
This concentration is about equimolar to the highest 
concentration ‘251-ER-MP21 used (1.1O-6 M). Clearly, 
the binding pattern of ER-MP21, revealing two affini- 
ties, was not significantly altered by the addition of irrel- 
evant mAb (Fig. 8, right). It is therefore unlikely that the 
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FIG. 8. (left) Scatchard analysis of ER-MP21 binding to R2C4 M&J precursor cells. Results from two representative experiments, revealing 
different numbers of binding sites, but similar affinities, are given. (middle) Scatchard analysis of ER-MP21 binding to RAW309Cr.l mature 
Mb cells in two different experiments. (right) Scatchard analysis of ER-MP21 binding to RAW309Cr.l cells in the presence (0) and absence 
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(0) of irrelevant rat IgG2a mAb ER-MPZO. 
low-affinity ER-MP21 receptor on RAW309Cr.l cells is 
identical to the Fc receptor. 
Thus, the different binding affinities of ER-MP21 to 
transferrin receptors on RAW309Cr.l and R2C4 cells 
suggest that transferrin receptors on mature and imma- 
ture M~#J are structurally different. 
DISCUSSION 
In search of mAbs directed against functionally im- 
portant epitopes on M4 precursor cells, we selected 
IgG2a mAb ER-MP21 for its inhibitory capacity of M$ 
development in M-CSF-stimulated bone marrow cul- 
tures. ER-MP21 appeared to be directed against the mu- 
rine transferrin receptor, since this mAb inhibited up- 
take of transferrin-bound 5gFe and precipitated, as the 
anti-transferrin receptor mAb H129.121, a homodimer 
of 200 kDa [ 161. Like other IgG anti-transferrin receptor 
mAbs [6, 7, 16, 271, ER-MP21 bound to an epitope 
different from the transferrin-binding site. 
In general, growth inhibition by anti-transferrin re- 
ceptor mAbs is caused by iron starvation of cells [4, 5, 
81. The underlying mechanism, proposed for IgG anti- 
transferrin receptor mAbs, is that mAb binding de- 
creases transferrin receptor recycling between the cell 
surface and intracellular compartments [8,28,29]. Fur- 
thermore, transferrin receptor degradation is enhanced, 
possibly by inappropriate intracellular routing of the 
complex consisting of transferrin, transferrin receptor, 
and mAb [5,29]. Both decreased recycling and enhanced 
degradation cause a reduced cell surface expression of 
transferrin receptors, leading to reduced iron uptake 
with concomitant growth inhibition in the presence of 
anti-transferrin receptor mAb. 
For M4 precursors, we indeed observed a strong inhi- 
bition of proliferation by anti-transferrin receptor mAb 
ER-MP21. Most likely, this inhibition is mediated by 
the mechanism described above. However, proliferation 
of more mature stages of M4 differentiation was hardly 
affected by ER-MP21. We observed this differentiation 
stage-related inhibition of M4 proliferation in two inde- 
pendent models of M$ differentiation, namely, M-CSF- 
stimulated bone marrow culture and a panel of M4 cell 
lines, aligned in differentiation sequence. Thus, with in- 
creasing maturity, proliferating M4 become refractory 
to inhibition by anti-transferrin receptor mAb. The 
highly sensitive M4 precursor cells are found around the 
CFU-GM/CFU-M stage of differentiation: CFU-M are 
the main M-CSF responsive cells in the bone marrow, 
and these were shown to be strongly inhibited (Fig. 4, 
left). Furthermore, the equally sensitive M$ precursor 
cell lines appear to be arrested around the CFU-GM 
stage of differentiation [2]. More mature, insensitive 
stages of differentiation, occurring at Day 4 of bone mar- 
row culture and represented by the mature Mr$ cell lines 
in the panel, are around the monoblast/monocyte stage 
P, 141. 
A comparable lack of growth inhibition by an anti- 
transferrin receptor mAb, inhibitory for other cell types, 
has been reported previously for murine L cells [4] as 
well as for different lymphocyte subsets [ 61. The mecha- 
nism of differential growth inhibition, however, re- 
mained largely obscure [7]. Our cell line model of M$ 
differentiation offered a unique opportunity to study this 
mechanism, since large numbers of cells with different 
sensitivities are available from a single hemopoietic lin- 
eage. In 5gFe-uptake studies, we observed that ER-MP21 
equally inhibited iron uptake by sensitive and insensi- 
tive M$ cell lines. Thus, the mechanism by which ER- 
MP21 blocks iron uptake is most likely similar for sensi- 
tive and insensitive cell lines. However, insensitive ma- 
ture M$ cell lines showed an iron uptake both in the 
presence and in the absence of ER-MP21 two to three 
times higher than that of immature M+ cell lines. Appar- 
ently, the diminished iron uptake by mature M4 cell 
lines, in the presence of the mAb, is still sufficient for 
undisturbed proliferation. In contrast, reduction of the 
lower level of iron uptake in Mb precursor cell lines 
caused by the action of the mAb, leads to severe inhibi- 
tion of proliferation or even cell death. This indicates 
that M4 precursor cell lines apply virtually all endocy- 
tosed iron for growth and proliferation, whereas mature 
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M4 cell lines normally take up more iron than needed 
merely for growth. A similar explanation is, most likely, 
valid for the differential growth inhibition of bone mar- 
row-derived M$: insensitive monoblasts/monocytes at 
Day 4 of culture may take up a multiple of the amount 
of iron taken up by CFU-M. 
HOW do mature Mb take up more iron than M4 pre- 
cursors? The most likely mechanism is the expression of 
an increased number of transferrin receptors [30]. In 
this study, we indeed observed for the mature WR19M.l 
cells a transferrin receptor expression higher than that 
of the investigated M4 precursor cell lines. This might 
serve as an explanation for increased iron uptake by 
WR19M.l cells. However, RAW309Cr.l cells showed a 
two to three times increased iron uptake, compared to 
that of M$J precursor cell lines, and yet expressed similar 
numbers of transferrin receptor on the cell surface. 
Thus, increased iron uptake is not necessarily accompa- 
nied by increased transferrin receptor expression. Our 
binding affinity analyses of ER-MP21 revealed that 
RAW309Cr.l transferrin receptors are presumably 
structurally different from transferrin receptors on M4 
precursors. ER-MP21 bound with single affinity to 
transferrin receptors on R2C4 cells, whereas two affini- 
ties were found for receptors on RAW309Cr.l cells. The 
high affinity binding-to the transferrin receptor-was 
more avid, compared to the binding to R2C4 cells, thus 
indicating a structural difference between the binding 
sites on both cell types. The low-affinity ER-MP21 re- 
ceptor on RAW309Cr.l cells appeared to be distinct 
from the receptor for the Fc part of IgG. Unfortunately, 
we have no further clues to its nature and relationship 
to the transferrin receptor. Interestingly in this context, 
Andreesen et al. [30] showed that mature human M4 
transferrin receptors bind their natural ligand transfer- 
rin with different affinity compared to that of other cell 
types, thus supporting the view that mature M+ express 
structurally different transferrin receptors. The present 
results suggest that structurally different transferrin re- 
ceptors on mature M4 account for a more efficient endo- 
cytosis of transferrin-bound iron. Increased efficiency in 
this respect is presumably mediated by an increased re- 
ceptor recycling of transferrin receptors between cell 
membrane and intracellular compartments. It is note- 
worthy that a similar increase in transferrin receptor 
recycling appears to occur during erythroid differentia- 
tion [31]. 
An alternative explanation for the increased iron up- 
take by mature M+--using the same number of transfer- 
rin receptors-might be the existence of additional 
pathways of iron uptake, independent from the transfer- 
rin receptor. For example, receptors for glycan moieties 
on transferrin, such as the asialoglycoprotein receptor 
or the mannose receptor, might mediate endocytosis of 
transferrin [32]. Moreover, fluid-phase endocytosis 
would be a highly feasible mechanism of alternative iron 
uptake for the actively endocytosing mature M$ [33]. 
Such alternative mechanisms would not be blocked by 
anti-transferrin receptor mAb ER-MP21. To investi- 
gate this possibility, we studied whether the competitive 
protein asialofetuin or the competitive saccharides man- 
nan and N-acetyl-glucosamine affected 5?Fe uptake by 
mature MQ, cell lines or caused increased inhibition of 
5!%‘e uptake in the presence of ER-MP21 (unpublished 
results). Unequivocally, these agents had no effects on 
cellular iron uptake. Furthermore, the level of fluid- 
phase endocytosis in mature M$, measured as uptake of 
5gFe-citrate, could by no means account for a two to three 
times increased iron uptake, compared to that of M$ 
precursor cells (data not shown). These alternative 
pathways of iron uptake must be excluded therefore as 
mechanisms of enhanced iron uptake by mature M$. 
Moreover, the similar relative inhibition of iron uptake 
by ER-MP21 for M4 precursor and mature M4 cell lines 
(Fig. 6, left) indicates that the same mechanism, i.e., 
transferrin receptor-mediated iron uptake, is active in 
both cell types. 
Why do mature M4 endocytose as much as two to 
three times the amount of iron needed for proliferation? 
Iron is incorporated in a number of vital proteins, such 
as heme-containing globins, cytochromes, and iron-con- 
taining enzymes. Furthermore, iron is stored intracellu- 
lady in ferritin 134,351. Mb are known to be an impor- 
tant link in the iron metabolism by the phagocytosis of 
senescent erythrocytes [36,37]. In connection with this, 
M$ constitute a considerable iron storage in the body. 
The development of this function is reflected by the in- 
creasing intracellular ferritin content during terminal 
differentiation of M~I [38]. Both the present results and 
those obtained by Andreesen et al. [30,38] suggest that 
mature M4 can accumulate iron for storage purposes, 
not only by phagocytosis of erythrocytes, but also by 
means of transferrin receptor-mediated iron uptake. 
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